摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-dimethylamino-3-methyl-2-oxobutane | 67082-24-0

中文名称
——
中文别名
——
英文名称
1-dimethylamino-3-methyl-2-oxobutane
英文别名
1-(Dimethylamino)-3-methylbutan-2-one
1-dimethylamino-3-methyl-2-oxobutane化学式
CAS
67082-24-0
化学式
C7H15NO
mdl
——
分子量
129.202
InChiKey
AFLHMEWCBVBIKP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    9
  • 可旋转键数:
    3
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.86
  • 拓扑面积:
    20.3
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    1-dimethylamino-3-methyl-2-oxobutane 在 Ru(OAc)2((S)-BINAP) 氢气 作用下, 以 甲醇 为溶剂, 反应 24.0h, 生成 (S)-1-Dimethylamino-3-methyl-butan-2-ol 、 (R)-1-Dimethylamino-3-methyl-butan-2-ol
    参考文献:
    名称:
    功能化酮的均相不对称氢化
    摘要:
    氢化 asymetrique en alcool de different cetones (aminocetones, cetols, cetoesters, cetoamides, cetothioester, cetoethers, dicetones, cetoacide) catalysee par des complexes du ruthenium(II) et du bis-diphenylphosphino-2,2'1'bina
    DOI:
    10.1021/ja00210a070
  • 作为产物:
    描述:
    2-isopropyl-3-nitro-oxirane 、 二甲胺乙醚 为溶剂, 生成 1-dimethylamino-3-methyl-2-oxobutane
    参考文献:
    名称:
    Sokolov,N.A. et al., Journal of Organic Chemistry USSR (English Translation), 1978, vol. 14, p. 478 - 479
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • New Drug Delivery System for Crossing the Blood Brain Barrier
    申请人:Lipshutz H. Bruce
    公开号:US20070203080A1
    公开(公告)日:2007-08-30
    New ubiquinol analogs are disclosed, as well as methods of using these compounds to deliver drug moieties to the body.
    新的泛醌类似物被披露,以及利用这些化合物将药物基团输送到人体的方法。
  • [EN] LINKED DIBENZIMIDAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS DU DIBENZIMIDAZOLE LIÉS
    申请人:ENANTA PHARM INC
    公开号:WO2010091413A1
    公开(公告)日:2010-08-12
    The present invention discloses linked dibenzimidazole derivatives, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    本发明公开了联苯二咪唑衍生物,或其药学上可接受的盐、酯或前药,其抑制含RNA的病毒,特别是丙型肝炎病毒(HCV)。因此,本发明的化合物干扰丙型肝炎病毒的生命周期,并且也可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物,用于治疗患有HCV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
  • HEPATITIS C VIRUS INHIBITORS
    申请人:Qiu Yao-Ling
    公开号:US20110064695A1
    公开(公告)日:2011-03-17
    The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.
    本发明公开了化合物的结构式(I),或其药学上可接受的盐、酯或前药: 这些化合物抑制RNA含病毒,特别是丙型肝炎病毒(HCV)。因此,本发明的化合物干扰丙型肝炎病毒的生命周期,并且也可用作抗病毒剂。本发明还涉及包含上述化合物的药物组合物,用于治疗患有HCV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。本发明涉及上述新型抗病毒化合物,包括含有这些化合物的药物组合物,以及用于治疗或预防受试者需要此类治疗的病毒(特别是HCV)感染的方法。
  • CORTICOSTEROID LINKED BETA-AGONIST COMPOUNDS FOR USE IN THERAPY
    申请人:Baker William R.
    公开号:US20090318396A1
    公开(公告)日:2009-12-24
    New chemical entities which comprise corticosteroids and phosphorylated β-agonists for use in therapy and compositions comprising and processes for preparing the same.
    新的化学实体包括皮质类固醇和磷酸化的β-激动剂,用于治疗以及包含这些化学实体的组合物和制备它们的方法。
  • [EN] PRODRUGS OF THERAPEUTIC COMPOUNDS<br/>[FR] PROMÉDICAMENTS DE COMPOSÉS THÉRAPEUTIQUES
    申请人:MYREXIS INC
    公开号:WO2012148550A1
    公开(公告)日:2012-11-01
    The present invention provides compounds, pharmaceutical compositions and medicaments comprising such compounds, and the use of these compounds, compositions, and medicaments in methods of treating diseases and disorders such as cancers.
    本发明提供了化合物、药物组合物和包含这些化合物的药物,以及在治疗癌症等疾病和疾病的方法中使用这些化合物、组合物和药物。
查看更多